IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
– First patient dosing commenced on May 19, 2023 – Trial enrollment completion and top line data expected in early 2024 POTOMAC, Md.–(BUSINESS WIRE)–#IGC–IGC Pharma, Inc (NYSE American: IGC) (“IGC”…
Details